武田制药Takeda Pharmaceutical（TAK）2025财年第三季度财报「NYSE」（英文版）（81页）.pdf

1、Takeda Quarterly Financial ReportFor the Quarter Ended December 31,2025Table of ContentsFinancial Highlights .3Selected Financial Results .3Revenue by Region .4Recent Developments .5Pipeline and R&D Activities .5Analysis of Results of Operations,Financial Position,and Cash Flows .11Results of Operat

2、ions .11Financial Position .18Cash Flows .20Forecast and Management Guidance .21Condensed Interim Consolidated Financial Statements .23(1)Condensed Interim Consolidated Statements of Profit or Loss .23(2)Condensed Interim Consolidated Statements of Comprehensive Income .24(3)Condensed Interim Consol

3、idated Statements of Financial Position .25(4)Condensed Interim Consolidated Statements of Changes in Equity .27(5)Condensed Interim Consolidated Statements of Cash Flows .29(6)Other Information .31Supplementary Information .321.Pipeline .33I.Clinical Development Activities .33II.Recent Pipeline Pro

4、gress in stage.41III.Projects removed from pipeline .43IV.Research&Development collaborations/partnering .442.Supplementary Revenue Information .49Revenue by region .49Year to date .49Quarterly .50Product Sales Analysis(vs PY Reported Actual).51Year to date .51Quarterly .53Q3 .53Product Sales Analys

5、is(Reported AER&Core CER Change).55Product Forecast .57Financial Appendix .Financial HighlightsSelected Financial ResultsTakeda uses certain non-IFRS measures to supplement the analysis of results of operations under International Financial Reporting Standards(IFRS).Refer to Financial Appendix for t

6、he definition and reconciliations of non-IFRS Measures.Financial ResultsNine-month Period Ended December 31,AER*CER*(JPY millions)20242025JPY Change%Change%ChangeRevenue3,528,1523,411,179(116,973)(3.3)%(2.8)%Operating profit417,518422,382 4,864 1.2%0.1%Profit before tax282,383312,668 30,284 10.7%7.7